Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Lancet Oncol

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    March 2017
  1. GULLEY JL, Rajan A, Spigel DR, Iannotti N, et al
    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Lancet Oncol. 2017 Mar 31. pii: S1470-2045(17)30240.
    PubMed     Text format     Abstract available


  2. TAKAHASHI T, Yamanaka T, Seto T, Harada H, et al
    Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30230.
    PubMed     Text format     Abstract available


  3. SLOTMAN BJ
    Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30193.
    PubMed     Text format    


  4. BROWER V
    Pravastatin has no advantage in small-cell lung cancer.
    Lancet Oncol. 2017 Mar 9. pii: S1470-2045(17)30184.
    PubMed     Text format    


    January 2017
  5. BURKI TK
    Treatment options not taken for non-small-cell lung cancer.
    Lancet Oncol. 2017 Jan 27. pii: S1470-2045(17)30066.
    PubMed     Text format    


  6. MAYOR S
    Osimertinib effective in EGFR T790M-positive lung cancer.
    Lancet Oncol. 2017;18:e9.
    PubMed     Text format    


    December 2016
  7. BROWER V
    Onartuzumab ineffective in non-small-cell lung cancer.
    Lancet Oncol. 2016 Dec 22. pii: S1470-2045(16)30680.
    PubMed     Text format    


  8. RUDIN CM, Pietanza MC, Bauer TM, Ready N, et al
    Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30565.
    PubMed     Text format     Abstract available


  9. HELLMANN MD, Rizvi NA, Goldman JW, Gettinger SN, et al
    Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30624.
    PubMed     Text format     Abstract available


  10. LIN JJ, Shaw AT
    Raising the bar on first-line immunotherapy in lung cancer.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30594.
    PubMed     Text format    


  11. ROSSI A
    Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30575.
    PubMed     Text format    


    November 2016
  12. GADGEEL SM
    Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Lancet Oncol. 2016 Nov 7. pii: S1470-2045(16)30567.
    PubMed     Text format    


  13. GETTINGER SN, Bazhenova LA, Langer CJ, Salgia R, et al
    Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Lancet Oncol. 2016 Nov 7. pii: S1470-2045(16)30392.
    PubMed     Text format     Abstract available


  14. NEAL JW, Dahlberg SE, Wakelee HA, Aisner SC, et al
    Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30561.
    PubMed     Text format     Abstract available


  15. ROSELL R, Karachaliou N
    RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30557.
    PubMed     Text format    


  16. DRILON A, Rekhtman N, Arcila M, Wang L, et al
    Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30562.
    PubMed     Text format     Abstract available


    October 2016
  17. GOMEZ DR, Blumenschein GR Jr, Lee JJ, Hernandez M, et al
    Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
    Lancet Oncol. 2016 Oct 24. pii: S1470-2045(16)30532.
    PubMed     Text format     Abstract available


  18. GOSS G, Tsai CM, Shepherd FA, Bazhenova L, et al
    Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Lancet Oncol. 2016 Oct 14. pii: S1470-2045(16)30508.
    PubMed     Text format     Abstract available


  19. LANGER CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, et al
    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Lancet Oncol. 2016 Oct 10. pii: S1470-2045(16)30498.
    PubMed     Text format     Abstract available


  20. LE PECHOUX C
    PCI in resected small-cell lung cancer - Author's reply.
    Lancet Oncol. 2016;17:e416.
    PubMed     Text format    


  21. KNISELY J, Sharma R, Goenka A, Halthore A, et al
    PCI in resected small-cell lung cancer.
    Lancet Oncol. 2016;17:e415.
    PubMed     Text format    


    September 2016
  22. UMEWENI N, Knight H, McVeigh G
    NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.
    Lancet Oncol. 2016 Sep 27. pii: S1470-2045(16)30488.
    PubMed     Text format    


  23. WALLINGTON M, Saxon EB, Bomb M, Smittenaar R, et al
    30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
    Lancet Oncol. 2016;17:1203-16.
    PubMed     Text format     Abstract available


    August 2016
  24. BURKI TK
    Predicting lung cancer prognosis using machine learning.
    Lancet Oncol. 2016 Aug 25. pii: S1470-2045(16)30436.
    PubMed     Text format    


  25. HALL CJ, Umeweni N, Knight H, Smith L, et al
    NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.
    Lancet Oncol. 2016 Aug 23. pii: S1470-2045(16)30435.
    PubMed     Text format    


  26. TAN WL, Jain A, Takano A, Newell EW, et al
    Novel therapeutic targets on the horizon for lung cancer.
    Lancet Oncol. 2016;17:e347-62.
    PubMed     Text format     Abstract available


  27. LICHT PB, Andersen C, Dan Jorgensen O, Bendixen M, et al
    Quality of life after video-assisted surgery for lung cancer - Author's reply.
    Lancet Oncol. 2016;17:e318-9.
    PubMed     Text format    


  28. NAKAZAWA S, Shimizu K, Nagashima T, Mogi A, et al
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e318.
    PubMed     Text format    


  29. THE VIOLET TRIALISTS CORRESPON
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e317.
    PubMed     Text format    


  30. VERONESI G, Novellis P, Park B
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e316-7.
    PubMed     Text format    


  31. MEHRAN RJ, Roth JA
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e315-6.
    PubMed     Text format    


    July 2016
  32. PECHOUX CL, Sun A, Slotman BJ, De Ruysscher D, et al
    Prophylactic cranial irradiation for patients with lung cancer.
    Lancet Oncol. 2016;17:e277-93.
    PubMed     Text format     Abstract available


    June 2016
  33. GOTO K, Ohe Y, Shibata T, Seto T, et al
    Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30104.
    PubMed     Text format     Abstract available


  34. KALEMKERIAN GP
    Combination chemotherapy for relapsed small-cell lung cancer.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30160.
    PubMed     Text format    


  35. BALDWIN DR, Devaraj A
    Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management.
    Lancet Oncol. 2016 Jun 6. pii: S1470-2045(16)30134.
    PubMed     Text format    


  36. WALTER JE, Heuvelmans MA, de Jong PA, Vliegenthart R, et al
    Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.
    Lancet Oncol. 2016 Jun 6. pii: S1470-2045(16)30069.
    PubMed     Text format     Abstract available


  37. ANTONIA SJ, Lopez-Martin JA, Bendell J, Ott PA, et al
    Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30098.
    PubMed     Text format     Abstract available


  38. LI Y, Wu YL
    Immunotherapy for small-cell lung cancer.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30159.
    PubMed     Text format    


  39. GOLDBERG SB, Gettinger SN, Mahajan A, Chiang AC, et al
    Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30053.
    PubMed     Text format     Abstract available


  40. PLANCHARD D, Besse B, Groen HJ, Souquet PJ, et al
    Dabrafenib plus trametinib in patients with previously treated BRAF-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30146.
    PubMed     Text format     Abstract available


    May 2016
  41. BENDIXEN M, Jorgensen OD, Kronborg C, Andersen C, et al
    Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.
    Lancet Oncol. 2016 May 6. pii: S1470-2045(16)00173.
    PubMed     Text format     Abstract available


    April 2016
  42. VANSTEENKISTE JF, Cho BC, Vanakesa T, De Pas T, et al
    Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)00099.
    PubMed     Text format     Abstract available


  43. QUOIX E
    Post-operative survival of patients with lung cancer.
    Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)30031.
    PubMed     Text format    


  44. PARK K, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
    Lancet Oncol. 2016 Apr 12. pii: S1470-2045(16)30033.
    PubMed     Text format     Abstract available


  45. PLANCHARD D, Kim TM, Mazieres J, Quoix E, et al
    Dabrafenib in patients with BRAF-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
    Lancet Oncol. 2016 Apr 11. pii: S1470-2045(16)00077.
    PubMed     Text format     Abstract available


    March 2016
  46. FIELD JK, Duffy SW
    Lung cancer CT screening: is annual screening necessary?
    Lancet Oncol. 2016 Mar 18. pii: S1470-2045(16)00079.
    PubMed     Text format    


  47. PATZ EF JR, Greco E, Gatsonis C, Pinsky P, et al
    Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.
    Lancet Oncol. 2016 Mar 18. pii: S1470-2045(15)00621.
    PubMed     Text format     Abstract available


  48. KIM DW, Mehra R, Tan DS, Felip E, et al
    Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Lancet Oncol. 2016 Mar 10. pii: S1470-2045(15)00614.
    PubMed     Text format     Abstract available


  49. BURKI TK
    Counting the cost of end-of-life cancer care.
    Lancet Oncol. 2016;17:e91.
    PubMed     Text format    


  50. GARON EB
    The race for combined checkpoint inhibition in NSCLC.
    Lancet Oncol. 2016;17:259-60.
    PubMed     Text format    


    February 2016
  51. TEMEL JS, Abernethy AP, Currow DC, Friend J, et al
    Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
    Lancet Oncol. 2016 Feb 19. pii: S1470-2045(15)00558.
    PubMed     Text format     Abstract available


  52. ANTONIA S, Goldberg SB, Balmanoukian A, Chaft JE, et al
    Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Lancet Oncol. 2016 Feb 5. pii: S1470-2045(15)00544.
    PubMed     Text format     Abstract available


  53. CHANG JY, Senan S, Smit EF, Roth JA, et al
    Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2016;17:e42-3.
    PubMed     Text format    


  54. KATZ MS, Husain ZA
    Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer.
    Lancet Oncol. 2016;17:e41-2.
    PubMed     Text format    


  55. RIESTERER O, Weder W, Stahel R
    Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? - Authors' reply.
    Lancet Oncol. 2016;17:e44-5.
    PubMed     Text format    


  56. RIMNER A, Simone CB 2nd, Zauderer MG, Cengel KA, et al
    Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?
    Lancet Oncol. 2016;17:e43-4.
    PubMed     Text format    


  57. HARDING E
    The Lake.
    Lancet Oncol. 2016;17:151.
    PubMed     Text format    


  58. BAKER H
    Familial risk in patients with carcinoma of unknown primary.
    Lancet Oncol. 2016;17:e48.
    PubMed     Text format    


  59. JASSEM J
    Alectinib in crizotinib-resistant, ALK-positive NSCLC.
    Lancet Oncol. 2016;17:134-5.
    PubMed     Text format    


    December 2015
  60. QUOIX E, Lena H, Losonczy G, Forget F, et al
    TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
    Lancet Oncol. 2015 Dec 22. pii: S1470-2045(15)00483.
    PubMed     Text format     Abstract available


  61. BUTTS CA, Sangha R
    TIME for a successful cancer vaccine in NSCLC?
    Lancet Oncol. 2015 Dec 22. pii: S1470-2045(15)00554.
    PubMed     Text format    


  62. SHAW AT, Gandhi L, Gadgeel S, Riely GJ, et al
    Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Lancet Oncol. 2015 Dec 18. pii: S1470-2045(15)00488.
    PubMed     Text format     Abstract available


  63. BROWER V
    Afatinib and chemotherapy in non-small-cell lung cancer.
    Lancet Oncol. 2015 Dec 17. pii: S1470-2045(15)00609.
    PubMed     Text format    


    October 2015
  64. WU Y, Spicer J
    Nedaplatin: a new platinum for squamous lung cancer?
    Lancet Oncol. 2015 Oct 27. pii: S1470-2045(15)00400.
    PubMed     Text format    


  65. BAKER H
    Overtreatment in stage IV lung cancer in the USA.
    Lancet Oncol. 2015 Oct 8. pii: S1470-2045(15)00383.
    PubMed     Text format    


  66. ZHANG I, Zaorsky NG, Palmer JD, Mehra R, et al
    Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
    Lancet Oncol. 2015;16:e510-21.
    PubMed     Text format     Abstract available


  67. FUSI A, Festino L, Botti G, Masucci G, et al
    PD-L1 expression as a potential predictive biomarker.
    Lancet Oncol. 2015;16:1285-7.
    PubMed     Text format    


    September 2015
  68. LANDMAN A
    16th World Conference on Lung Cancer.
    Lancet Oncol. 2015 Sep 17. pii: S1470-2045(15)00337.
    PubMed     Text format    


  69. TAN CS, Gilligan D, Pacey S
    Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
    Lancet Oncol. 2015;16:e447-59.
    PubMed     Text format     Abstract available


  70. VASSAL G, Blanc P, Copland C, Pearson A, et al
    Will the revised class waiver list make it?
    Lancet Oncol. 2015;16:e425-6.
    PubMed     Text format    


  71. RICE D, Sepesi B, Heymach J, Swisher S, et al
    SABR vs surgery for NSCLC in the media.
    Lancet Oncol. 2015;16:e422.
    PubMed     Text format    


    August 2015
  72. CHANG JY, Senan S, Smit EF, Roth JA, et al
    Surgery versus SABR for resectable non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2015;16:e374-5.
    PubMed     Text format    


  73. DEARMAN C, van As N, Crellin A, Slevin N, et al
    Surgery versus SABR for resectable non-small-cell lung cancer.
    Lancet Oncol. 2015;16:e373-4.
    PubMed     Text format    


  74. HAMAJI M, Groth SS, Sugarbaker DJ, Burt BM, et al
    Surgery versus SABR for resectable non-small-cell lung cancer.
    Lancet Oncol. 2015;16:e372.
    PubMed     Text format    


  75. OPITZ I, Rocco G, Brunelli A, Varela G, et al
    Surgery versus SABR for resectable non-small-cell lung cancer.
    Lancet Oncol. 2015;16:e372-3.
    PubMed     Text format    


  76. ZHANG L, Tian J, Wang C
    Surgery versus SABR for resectable non-small-cell lung cancer.
    Lancet Oncol. 2015;16:e371-2.
    PubMed     Text format    


  77. CAO C, D'Amico T, Demmy T, Dunning J, et al
    Surgery versus SABR for resectable non-small-cell lung cancer.
    Lancet Oncol. 2015;16:e370-1.
    PubMed     Text format    


  78. SORIA JC, Felip E, Cobo M, Lu S, et al
    Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Lancet Oncol. 2015;16:897-907.
    PubMed     Text format     Abstract available


  79. GUNJUR A
    The perceptions of a surgical cure.
    Lancet Oncol. 2015;16:e380.
    PubMed     Text format    


    July 2015
  80. HALL CJ, Hay N, George E, Adler AI, et al
    NICE guidance on nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer.
    Lancet Oncol. 2015 Jul 21. pii: S1470-2045(15)00189.
    PubMed     Text format    


  81. SORIA JC, Wu YL, Nakagawa K, Kim SW, et al
    Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Lancet Oncol. 2015 Jul 6. pii: S1470-2045(15)00121.
    PubMed     Text format     Abstract available


  82. HIRSCH FR, Herbst RS, Gandara DR
    EGFR tyrosine kinase inhibitors in squamous cell lung cancer.
    Lancet Oncol. 2015 Jul 3. pii: S1470-2045(15)00126.
    PubMed     Text format    


  83. CHEN B, Hu B, Li W, Xue J, et al
    Transformation from NSCLC to SCLC: when did it happen?
    Lancet Oncol. 2015;16:e309.
    PubMed     Text format    


  84. ENGELMAN JA, Oser MG, Niederst MJ, Sequist LV, et al
    Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.
    Lancet Oncol. 2015;16:e309-10.
    PubMed     Text format    


  85. DEVARAKONDA S, Morgensztern D, Govindan R
    Genomic alterations in lung adenocarcinoma.
    Lancet Oncol. 2015;16:e342-51.
    PubMed     Text format     Abstract available


  86. TORRI V, Broggini M, Garassino MC
    EGFR mutations and EGFR tyrosine kinase inhibitors.
    Lancet Oncol. 2015;16:746-8.
    PubMed     Text format    


    June 2015
  87. YAQUB F
    Nivolumab for squamous-cell non-small-cell lung cancer.
    Lancet Oncol. 2015 Jun 6. pii: S1470-2045(15)00033.
    PubMed     Text format    


  88. YANG JC, Sequist LV, Geater SL, Tsai CM, et al
    Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
    Lancet Oncol. 2015 Jun 4. pii: S1470-2045(15)00026.
    PubMed     Text format     Abstract available


  89. SCHILLER JH
    Anti-EGFR monoclonal antibodies in lung cancer treatment.
    Lancet Oncol. 2015 Jun 1. pii: S1470-2045(15)00020.
    PubMed     Text format    


  90. THATCHER N, Hirsch FR, Luft AV, Szczesna A, et al
    Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Lancet Oncol. 2015 Jun 1. pii: S1470-2045(15)00021.
    PubMed     Text format     Abstract available


  91. YAQUB F
    ASTRO issues new guidance for radiotherapy in NSCLC.
    Lancet Oncol. 2015;16:e268.
    PubMed     Text format    


  92. YAQUB F
    Potential new treatments for EGFR-inhibitor-resistant NSCLC.
    Lancet Oncol. 2015;16:e268.
    PubMed     Text format    


    May 2015
  93. TREASURE T, Rintoul RC, Macbeth F
    SABR in early operable lung cancer: time for evidence.
    Lancet Oncol. 2015 May 13. pii: S1470-2045(15)70225.
    PubMed     Text format    


  94. CHANG JY, Senan S, Paul MA, Mehran RJ, et al
    Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
    Lancet Oncol. 2015 May 13. pii: S1470-2045(15)70168.
    PubMed     Text format     Abstract available


  95. GRUBER K
    BRCA2 variant aerodigestive cancer risk.
    Lancet Oncol. 2015;16:e204.
    PubMed     Text format    


    April 2015
  96. BELDERBOS J, Walraven I, van Diessen J, Verheij M, et al
    Radiotherapy dose and fractionation for stage III NSCLC.
    Lancet Oncol. 2015;16:e156-7.
    PubMed     Text format    


  97. GARASSINO MC, Marsoni S
    A lesson from vorinostat in pleural mesothelioma.
    Lancet Oncol. 2015;16:359-60.
    PubMed     Text format    


  98. KRUG LM, Kindler HL, Calvert H, Manegold C, et al
    Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Oncol. 2015;16:447-56.
    PubMed     Text format     Abstract available


    March 2015
  99. ZHOU F, Zhou C
    Necitumumab for patients with non-squamous NSCLC: uninspiring results.
    Lancet Oncol. 2015;16:246-7.
    PubMed     Text format    


  100. MAYOR S
    Side-effects of cancer drugs are under-reported in trials.
    Lancet Oncol. 2015;16:e107.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: